Egypt’s Eva Pharma on Monday signed an agreement to provide India with 300,000 doses of remdesivir, used in the treatment of COVID-19, the company said in a statement.
The agreement, which was signed at the Indian embassy in Cairo, is aimed at helping India combat a surge in infections which has overwhelmed the health system and held close to record daily highs on Monday.
Eva Pharma, a generic drugmaker established in 1997, said in June 2020 it had received a license from Gilead Sciences Inc to make remdesivir in Egypt and distribute it in 127 countries.
The drug targets moderate to severe cases of COVID-19 in intensive care who require oxygen.
Eva Pharma didn’t disclose the deal’s value.
- India bans anti-viral Remdesivir exports as COVID-19 rages on, rallies continue
- Coronavirus: WHO advises against use of Gilead’s remdesivir for hospitalized patients
- Critical care body advises against remdesivir for severely ill coronavirus patients
- WHO defends remdesivir trial results showing it doesn’t help COVID-19 patients